Currently, CNMD's trailing twelve months (TTM) EPS stands at $1.85, according to the most recent financial reports. In 2025, CNMD reported a per-share earnings of $1.52, which represents a decrease compared to the EPS of $4.29 recorded in 2024. CNMD recorded an EPS of $0.77 for the quarterly period ending on Jun 30, 2026.
In 2025, CONMED's EPS was $1.52, a decrease of 64.6% from $4.29 in 2024. For the quarter ending Jun 30, 2026, the EPS was $0.77, reflecting a 11.6% increase compared to the same quarter a year earlier. The trailing twelve months (TTM) EPS as of June 2026 is $1.85. In 2024, the annual EPS was $4.29, showing an increase of 104.3% compared to 2023.
CONMED has recorded a growth in earnings per share of 11.6% over the past 12 months (YoY, quarterly). CONMED had an average annual EPS growth of 35.7% over the last five years. Over the last decade, CNMD had an average annual earnings per share growth of 3.3%.
| Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
|---|---|---|---|---|
| BSX Boston Scientific Corp | 20.07 | 55.6% | 63.3% | N/A |
| MDT Medtronic Plc | 23.21 | 3.3% | 9.8% | 6.9% |
| CNMD CONMED Corp | 26.88 | -64.6% | N/A | 35.7% |
| JNJ Johnson & Johnson | 28.86 | 90.6% | 17.7% | 14.8% |
| SYK Stryker Corp | 34.31 | 8% | 10.9% | 14.8% |
| TFX Teleflex Incorporated | N/A | -1,462.4% | N/A | N/A |
| IART Integra Lifesciences Holdings Corp | N/A | -7,388.9% | N/A | N/A |
All data is based on quarterly TTM periods, unless otherwise specified.